Core Viewpoint - 瑞丽医美 (02135.HK) reported a significant decline in revenue and an increase in losses for the first half of 2025, indicating challenges in the medical aesthetics industry due to intense competition and a decrease in active customer numbers [1] Financial Performance - The company's revenue for the first half of 2025 was RMB 84.598 million, representing a year-on-year decrease of 27.99% [1] - The loss attributable to the parent company for the period was RMB 7.57 million, compared to a loss of RMB 1.617 million in the same period last year [1] - Basic loss per share was 1.36 cents [1] Revenue Breakdown - Revenue from medical aesthetic services was approximately RMB 74.90 million, a decline of about 9.7% compared to approximately RMB 83.00 million for the six months ending June 30, 2024 [1] - The decrease in revenue was attributed to a drop in the number of active customers, which could not be offset by an increase in average transaction value [1] - Both minimally invasive beauty services and skin beauty services experienced a reduction in revenue [1]

Core Points - Ruili Medical Beauty (02135) reported a revenue of 84.598 million yuan for the six months ending June 30, 2025, representing a year-on-year decrease of 27.99% [1] - The company recorded a loss attributable to equity holders of 7.57 million yuan, an increase of 368.15% compared to the previous year [1] - The loss per share was 1.36 cents [1] Revenue Breakdown - Revenue from medical beauty services was approximately 74.90 million yuan, down about 9.7% from approximately 83.00 million yuan for the six months ending June 30, 2024 [1] - The decline in revenue was attributed to a decrease in the number of active customers due to intense industry competition, which could not be offset by an increase in average transaction value [1] - Revenue from minimally invasive beauty services and skin beauty services decreased as a result of the reduced active customer base [1]

Group 1 - The core viewpoint of the news highlights the recent performance of Rui Li Medical Beauty, which saw a stock price increase of 9.32% despite a cumulative decline of 6.35% over the past month, while the Hang Seng Index dropped by 1.6% [1][2] - Financial data indicates that Rui Li Medical Beauty achieved total revenue of 199 million yuan, a year-on-year increase of 5.26%, but reported a net loss of 59.21 million yuan, a significant decrease of 82.43% compared to the previous year [2] - The company's gross profit margin stands at 35.82%, with a debt-to-asset ratio of 61.78% [2] Group 2 - Currently, there are no institutional investment ratings for Rui Li Medical Beauty, and its price-to-earnings ratio is -1.03, ranking 101st in the healthcare equipment and services industry, which has an average TTM P/E ratio of -1.13 [3] - The company operates as a leading medical beauty service provider in Zhejiang, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services, along with consulting services for third-party medical beauty institutions [4] - Rui Li Medical Beauty has expanded its service network over 14 years, operating four private profit-making medical beauty service institutions in China, with over 30 practicing physicians averaging more than ten years of industry experience [4]